Novo Nordisk (NVO)

[winston]

vested

Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound

by ED CARSON

The next-generation obesity drug CagriSema failed to match the weight loss from Eli Lilly's tirzepatide after 84 weeks.

Lilly is expected to FDA approval for an oral weight-loss drug in the second quarter.

Source: IBD

https://www.investors.com/news/technolo ... src=A00220

[winston]

vested

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock

by Rich Smith

The Food and Drug Administration (FDA) approved oral Wegovy in December, and oral Ozempic last month.

FCF projected to grow at 17.5% annually over the next five years.

Novo Nordisk currently paying a strong 3.8% dividend yield.

Source: The Motley Fool

https://finance.yahoo.com/news/1-reason ... 00435.html

[winston]

vested

Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027.

The move aims to make the treatments more accessible to patients with insurance coverage, particularly people with high-deductible health plans or co-insurance benefit designs.

The obesity injection Wegovy, its new pill counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus will have a new lower list price of $675 per month starting on Jan. 1, 2027.

Source: Phillips

[winston]

vested

This Stock’s Brutal Sell-Off Might Be a Buying Opportunity

by Rich Duprey

The CagriSema miss was undeniably disappointing and justified some near-term pain. Yet it is far from the devastating blow the market reaction implies.

CagriSema still produced clinically meaningful weight loss with a novel therapy that could still shine as development continues.

Meanwhile, UBT251’s strong early readout keeps Novo firmly in the hunt.

After the selloff, Novo Nordisk trades at an historically low PE of 11 and 15x free cash flow.

For a company with blockbuster franchises, robust cash flow, and a deep pipeline, this stumble may ultimately prove to be an attractive entry point for patient investors willing to look past the headlines.

Source: Money Morning

https://tradesoftheday.com/2026/02/26/t ... portunity/

[behappyalways]

Why Novo Nordisk’s Weight Loss Pill Has Taken Off
https://m.youtube.com/watch?v=Afl0WbuD0 ... kKAYcqIYzv

[winston]

not vested

Novo Nordisk 1Q26 Adjusted Operating Profit Falls 15% YoY, Beats Forecast

Novo Nordisk, the maker of weight-loss drug Wegovy, announced its quarterly results.

Adjusted operating profit for 1Q26 amounted to 32.86 billion Danish kroner (USD5.16 billion), down 15% YoY, or down 6% YoY at constant exchange rates, above market expectations of 28.74 billion Danish kroner.

Quarterly net sales rose 24% YoY to 96.823 billion Danish kroner, or up 32% YoY at constant exchange rates.

The company expects full-year adjusted sales and operating profit to decline by 4% to 12% at constant exchange rates, compared with its previous forecast range of a 5% to 13% decline.

CEO Mike Doustdar said in a statement that the strong performance of Wegovy, coupled with continued growth in international operations, prompted the company to raise its related guidance.

Novo Nordisk had enjoyed a window as the only oral weight-loss drug provider in the US market, but this period ended early last month after a competing drug, Foundayo, developed by Eli Lilly and Company (LLY.US) received approval from the US Food and Drug Administration.

Eli Lilly and Company also raised its full-year earnings and revenue forecasts last week.

Source: AASTOCKS Financial News

http://www.aastocks.com/en/stocks/news/ ... -news/AAFN